Chebulagic acid from Terminalia chebula enhances insulin mediated glucose uptake in 3T3-L1 adipocytes via PPARγ signaling pathway

BioFactors

Volumn 40, Issue 6, 2014, Pages 646-657

  Shyni, Gangadharan Leela ^a   Kavitha, Sasidharan ^a   Indu, Sasidharan ^a   Arya, Anil Das ^a   Anusree, Sasidharan Suseela ^a   Vineetha, Vadavanath Prabhakaran ^a   Vandana, Sankar ^a   Sundaresan, Andikannu ^a   Raghu, Kozhiparambil Gopalan ^a  

^a REGIONAL RESEARCH LABORATORY CSIR   (India)

Author keywords

Adipogenesis; Adiponectin; C EBP ; Chebulagic acid; GLUT4; PPAR ; Type 2 diabetes

Indexed keywords

ADIPONECTIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CHEBULAGIC ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; ADIPOQ PROTEIN, MOUSE; ANTIDIABETIC AGENT; BENZOPYRAN DERIVATIVE; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, MOUSE; GLUCOSIDE; METHANOL; PLANT EXTRACT; SLC2A4 PROTEIN, MOUSE; SOLVENT;

3T3 CELL LINE; ADIPOCYTE; ADIPOGENESIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOCRINE FUNCTION; FRUIT; GENE EXPRESSION PROFILING; GLUCOSE TRANSPORT; INSULIN SENSITIVITY; LIGAND BINDING; MOLECULAR DOCKING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TERMINALIA CHEBULA; AGONISTS; ANIMAL; CELL DIFFERENTIATION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INSULIN RESISTANCE; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; TERMINALIA; TRANSPORT AT THE CELLULAR LEVEL;

TERMINALIA CHEBULA;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPONECTIN; ANIMALS; BENZOPYRANS; BIOLOGICAL TRANSPORT; CCAAT-ENHANCER-BINDING PROTEINS; CELL DIFFERENTIATION; FRUIT; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; GLUCOSIDES; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METHANOL; MICE; MOLECULAR DOCKING SIMULATION; PLANT EXTRACTS; PPAR GAMMA; SIGNAL TRANSDUCTION; SOLVENTS; TERMINALIA;

EID: 84920988790     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1193     Document Type: Article

References (49)

1. Whiting, D.R., Guariguata, L., Weil, C., and Shaw, J. (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabet. Res. Clin. Pract.94, 311-321.
2. DeFronzo, R.A. and Ferrannini, E. (1991) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabet. Care3, 173-194.
3. Ralph, A. and DeFronzo, M.D. (1999) Pharmacologic therapy for type 2 diabetes mellitus. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med.4, 281-303.
4. Balakumar, P., Rose, M., Ganti, S.S., Krishan, P., and Singh, M. (2007) PPAR dual agonists: are they opening Pandora's Box. Pharmacol. Res.56, 91-98.
5. Semple, R.K., Chatterjee, V.K., and O'Rahilly S. (2006) PPAR gamma and human metabolic disease. J. Clin. Invest.116, 581-589.
6. Guan, Y., Hao, C., Cha, D.R., Rao, R., Lu, W., et al. (2005) Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat. Med.11, 861-866.
7. Pan, H.J., Lin, Y., Chen, Y.E., Vance, D.E., and Leiter, E.H. (2006) Adverse hepatic and cardiac response s to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidyl choline metabolism. Vasc. Pharmacol.45, 65-71.
8. Bhalla, K., Hwang, B.J., Choi, J.H., Dewi, R., Ou, L., et al. (2011) N-acetyl farnesyl cysteine is a novel class of PPAR{gamma} ligand with partial and full agonist activity in vitro and in vivo. J. Biol. Chem.286, 41626-41635.
9. Agrawal, R., Jain, P., and Dikshit, S.N. (2012) Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (gamma) agonist. Mini Rev. Med. Chem.12, 87-89.
10. Atanasov, A.G., Wang, J.N., Gu, S.P., Bu, J., Kramer, M.P., et al. (2013) Honokiol: a non-adipogenic PPARγ agonist from nature. Biochem. Biophys. Acta 1830, 4813-4819.
11. Newman, D.J. and Cragg, G.M. (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod.75, 311-335.
12. Chen, L., Li, Q.Y., Shi, X.J., Mao, S.L., and Du, Y.L. (2013) 6-Hydroxydaidzein enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells. J. Agric. Food Chem.61, 10714-10719.
13. Shin, E., Choi, K.M., Yoo, H.S., Lee, C.K., Hwang, B.Y., et al. (2010) Inhibitory effects of coumarins from the stem barks of Fraxinus rhynchophylla on adipocyte differentiation in 3T3-L1 cells. Biol. Pharm. Bull.33, 1610-1614.
14. Anusree, S.S., Priyanka, A., Nisha, V.M., Das, A.A., and Raghu, K.G. (2014) An in vitro study reveals the nutraceutical potential of punicic acid relevant to diabetes via enhanced GLUT4 expression and adiponectin secretion. Food Funct.10, 2590-2601.
15. Riya, M.P., Antu, K.A., Pal, S., Chandrakanth, K.C., Anilkumar, K.S., Tamrakar, A.K., Srivastava, A.K., and Raghu, K.G. (2014) Antidiabetic property of Aerva lanata (L) Juss. ex Schult. is mediated by inhibition of alpha glucosidase, protein glycation and stimulation of adipogenesis. J. Diabet. doi: 10.1111/1753-0407.12216. [Epub ahead of print]
16. Riya, M.P., Antu, K.A., Vinu, T., Chandrakanth, K.C., Anilkumar, K.S., et al. (2014) An in vitro study reveals nutraceutical properties of Ananas comosus (L.) Merr. var. Mauritius fruit residue beneficial to diabetes. J. Sci. Food Agric.30, 943-950.
17. Verma, N., Singh, A.P., Amresh, G., Sahub, P.K., Singha, A., et al. (2011) Review on wonderful and miraculous triphala. J. Pharm. Res.4, 690-694.
18. Pfundstein, B., El Desouky, S.K., Hull, W.E., Haubner, R., Erben, G., et al. (2010) Polyphenolic compounds in the fruits of Egyptian medicinal plants (Terminalia bellerica, Terminalia chebula, and Terminalia horrida): characterization, quantitation and determination of antioxidant capacities. Phytochemistry71, 1132-1148.
19. Lee, H.S., Jung, S.H., Yun, B.S., and Lee, K.W. (2006) Isolation of chebulagic acid from Terminalia chebula Retz and its antioxidant effect in isolated rat hepatocytes. Arch. Toxicol.81, 211-218.
20. Yang, M.H., Vasquez, Y., Ali, Z., Khan, I.A. and Khan, S.I. (2013) Constituents from Terminalia species increase PPAR α and PPARγ levels and stimulate glucose uptake without enhancing adipocytes differentiation. J. Ethanopharmacol.16, 490-498.
21. Hansen, J.B., Petersen, R.K., Larsen, B.M., Bartkova, J., Alsner, J., et al. (1999) Activation of peroxisome proliferator activated receptor protein in adipocyte differentiation. J. Biol. Chem.274, 2386-2393.
22. Quan, X., Wang, Y., Ma, X., Liang, Y., Tian, W., et al (2012) α-Mangostin induces apoptosis and suppresses differentiation of 3T3-L1 cells via inhibiting fatty acid synthase. PLoS One7, e33376-e33378.
23. Kasturi, R. and Joshi, V.C. (1982) Hormonal regulation of stearoyl coenzyme A desaturase activity and lipogenesis during adipose conversion of 3T3-L1 cells. J. Biol. Chem.257, 12224-12230.
24. Engvall, E. and Perlman, P. (1971) Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry8, 871-874.
25. Chen, Q.C., Zhang, W.Y., Jin, W., Lee, I.S., Min, B.S., et al. (2010) Flavonoids and isoflavonoids from Sophorae flos improve glucose uptake in vitro. Plant. Med.76, 79-81.
26. Hsu, K.C., Chen, Y.F., Lin, S.R., and Yang, J.M. (2011) iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinform.12, 1-S33.
27. Mahindroo, N., Wang, C.C., Liao, C.C., Huang, C.F., Lu, I.L., et al. (2006) Indol-1-yl acetic acids as peroxisome proliferator activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. J. Med. Chem.49, 1212-1216.
28. Medina-Gomez, G., Gray, S., and Vidal-Puig, A. (2007) Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr.10, 1132-11347.
29. Guasch, L., Sala, E., Valls, C., Blay, M., Mulero, M., et al. (2011) Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity. J. Comput. Aided Mol. Des.25, 717-728.
30. Choi, J.H., Banks, A.S., Estall, J.L., Kajimura, S., Boström, P., et al. (2010) Anti-diabetic drugs inhibit obesitylinked phosphorylation of PPARgamma by Cdk5. Nature466, 451-456.
31. Scher, P., Braissant, O., Basu-Modak, S., Michalik, L., Wahli, W., et al. (2001) Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology142, 4195-4202.
32. Werman, A., Hollenberg, A., Solanes, G., Bjorbaek, C., Vidal-Puig, AJ., et al. (1997) Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J. Biol. Chem.272, 20230-20235.
33. Ren, D., Collingwood, T.N., Rebar, E.J., Wolffe, A.P., and Camp, H.S. (2002) PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev.16, 27-32.
34. Vidal-Puig, A., Jimenez-Linan, M., Lowell, B.B., Hamann, A., Hu, E., et al. (1996) Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J. Clin. Invest.97, 2553-2561.
35. Vidal-Puig, A.J., Considine, R.V., Jimenez-Linan, M., Werman, A., Pories, W.J., et al. (1997) Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest.99, 2416-2422.
36. Zhang, J., Fu, M., Cui, T., Xiong, C., Xu, K., et al. (2004) Selective disruption of PPAR{gamma}2 impairs the development of adipose tissue and insulin sensitivity. Proc. Natl. Acad. Sci. USA101, 10703-10708.
37. Uno, K., Katagiri, H., Yamada, T., Ishigaki, Y., Ogihara, T., et al. (2006) Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science312, 1656-1659.
38. James, D.E., Hiken, J., and Lawrence, J.C. (1989) Jr Isoproterenol stimulates phosphorylation of the insulin regulatable glucose transporter in rat adipocytes. Proc. Natl. Acad. Sci. USA86, 8368-8383.
39. Douen, A.G., Ramlal, T., Rastogi, S., Bilan, P.J., Cartee, G.D., et al. (1990) Exercise induces recruitment of the insulin-responsive glucose transporter. J. Biol. Chem.265, 13427-13430.
40. Birnbaum, M.J. (1989) Identification of a novel gene encoding an insulin responsive glucose transporter protein. Cell57, 305-335.
41. Zorzano, A., Wilkinson, W., Kotliar, N.G., Wadzinkski, B.E., Ruoho, A.E., et al. (1989) Insulin-regulated glucose uptake in rat adipocytes is mediated by two transporter isoforms present in at least two vesicle populations. J. Biol. Chem.264, 12358-12363.
42. Huang, Y.N., Zhao, D.D., Gao, B., Zhong, K., Zhu, R.X., et al. (2012) Anti-hyperglycemic effect of chebulagic acid from the fruits of Terminalia chebula retz. Int. J. Mol. Sci.13, 6320-6333.
43. Karsten, S. (2014) Metabolic profiling in diabetes. J. Endocrinol.221, R75-R85.
44. Waki, H. and Tontonoz, P. (2007) Endocrine functions of adipose tissue. Annu. Rev. Pathol.2, 31-56.
45. Berg, A.H., Combs, T.P., and Scherer, P.E. (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab.13, 84-89.
46. Cushman, S.W. and Wardzala, L.J. (1980) Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane. J. Biol. Chem.255, 4758-4762.
47. Lakshmanan, J., Elmendorf, J.S., and Ozcan, S. (2003) Analysis of insulin stimulated glucose uptake in differentiated 3T3-L1 adipocytes. Methods Mol. Med.83, 97-103.
48. Green, H. and Kehinde, O. (1979) Formation of normally differentiated subcutaneous fat pads by an established preadipose cell line. J. Cell Physiol.101, 169-171.
49. Adeeb, S., Waqas, I., Omer, S., and Young, S.L. (2012) Adiponectin: Regulation of its production and its role in human diseases. Hormones11, 8-20.